AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor

Pancreatic cancer is one of the leading causes of cancer deaths, with pancreatic ductal adenocarcinoma (PDAC) being the most common subtype. Advanced stage diagnosis of PDAC is common, causing limited treatment opportunities. Gemcitabine is a frequently used chemotherapeutic agent which can be used...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2023-11, Vol.18 (11), p.e0294065-e0294065
Hauptverfasser:	Ingle, Komala, LaComb, Joseph F, Graves, Lee M, Baines, Antonio T, Bialkowska, Agnieszka B
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase Adenocarcinoma AKT protein Antimitotic agents Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antitumor activity Apoptosis Biology and Life Sciences Cancer Cancer therapies Carcinoma, Pancreatic Ductal - pathology Cell cycle Cell growth Cell Line, Tumor Cell Proliferation Cell survival Cell viability Chemoresistance Chemotherapy Comparative analysis Computer and Information Sciences Drug therapy Engineering and Technology Gemcitabine Growth Inhibitors - pharmacology Health aspects Humans Kinases Medical prognosis Medicine and Health Sciences Metabolism Metastasis Mutation Pancreatic cancer Pancreatic Neoplasms - pathology Penicillin Phosphatidylinositol 3-Kinases - metabolism Phosphoinositide-3 Kinase Inhibitors - pharmacology Phosphorylation Prostate cancer Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proteins Radiation therapy Research and Analysis Methods Testing TOR protein TOR Serine-Threonine Kinases Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!